1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
V Foundation 2027 Adult Translational Cancer Research Award is sponsored by V Foundation for Cancer Research. This award funds innovative research with the potential for high impact in adult cancer. Translational research in interventional oncology for HCC would be highly relevant to this program's goals.
An LOI is required by November 13, 2026.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Open to institutions and researchers focused on adult translational cancer research. Universities are eligible. Confirm the full requirements in the official notice before applying.
Applications for V Foundation 2027 Adult Translational Cancer Research Award are due November 13, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
V Foundation 2027 Adult Translational Cancer Research Award is funded by V Foundation for Cancer Research. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
RFA-RM-27-008 funds one or two U24 centers to sequence 6,000-10,000 pediatric samples a year for Gabriella Miller Kids First. Due January 8, 2027. Who can compete.
Read articleProp. 38, the $8.4 billion immunology research bond, led 56% to 44% the morning after the November 3, 2026 election. Here is what the statute says about who can get the grant money, the 20% indirect cap, and the timeline.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read article